Amgen, Xencor In Development Deal
socalTECH
JANUARY 6, 2011
Thousand Oaks-based Amgen , and Monrovia-based Xencor said Thursday that the two firms are in a co-development dual around a new novel antibody for treating autoimmune diseases. The firms said that XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases. READ MORE>>.
Let's personalize your content